Xeltis announces positive data for Xabg, its coronary artery bypass conduit, in EU clinical trial
- Preliminary clinical data from Xabg, Xeltis’ coronary artery bypass conduit (CABG), demonstrating positive safety and patency
- In an earlier, separate trial, Xabg recently demonstrated patency with excellent flow in a 24-month trial – the first time ever this duration has been achieved
- Supports potential of Xabg to transform CABG surgery landscape and eliminate need for vein harvesting
EINDHOVEN, The Netherlands, 17 July 2025 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces encouraging preliminary data for Xabg, its coronary artery bypass conduit (CABG), demonstrating positive safety and patency among patients with multi-vessel atherosclerotic coronary artery disease.
